Patents Assigned to PamGene B.V.
-
Patent number: 11802315Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with non-small-cell lung carcinoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non-small-cell lung carcinoma to specific medicaments. More specifically, the present invention provides methods which measure kinase-activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in blood samples of said patients.Type: GrantFiled: August 9, 2018Date of Patent: October 31, 2023Assignees: PamGene B.V., Erasmus University Medical Center RotterdamInventors: Robby Ruijtenbeek, Dirgje Maria Adriana Van Den Heuvel, Richard De Wijn, Joan Gertrudis Jacobus Victor Aerts, Adrianus Henricus Josephus Mathijssen
-
Publication number: 20230304067Abstract: The present invention provides methods for predicting the response of a patient in need of an immune checkpoint inhibitor (ICI), to treatment with a programmed cell death-1 (PD-1) or programmed death-ligand 1 (PD-L1) ICI, comprising the steps of: (a) measuring the kinase activity of at least two kinases independently selected from within at least two families of kinases selected from the group consisting of: the VEGFR or PDGFR family of kinases; the SRC family of kinases; the SYK family of kinases; the TAM family of kinases; the JakA family of kinases; and the ALK family of kinases, in a blood sample obtained from said patient, thereby providing a kinase activity profile of said blood sample; and (b) predicting from said kinase activity profile the response of said patient to treatment with said PD-1 or PD-L1 ICI, and kits for predicting the response of a patient in need of an ICI to treatment with a PD-1 or PD-L1 ICI.Type: ApplicationFiled: September 3, 2021Publication date: September 28, 2023Applicant: PamGene B.V.Inventor: Richard DE WIJN
-
Publication number: 20200232043Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with non-small-cell lung carcinoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non-small-cell lung carcinoma to specific medicaments. More specifically, the present invention provides methods which measure kinase-activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in blood samples of said patients.Type: ApplicationFiled: August 9, 2018Publication date: July 23, 2020Applicants: PamGene B.V., Erasmus University Medical Center RotterdamInventors: Robby Ruijtenbeek, Dirgje Maria Adríana Van Den Heuvei, Richard De Wijn, Joan Gertrudis Jacobus Victor Aerts, Adrianus Henricus Josephus Mathijssen
-
Patent number: 9448237Abstract: The present invention relates to a method and tools which allow the kinetic monitoring of hydrolase enzyme activity. The present invention also aims to provide synthetic peptides and peptide residues modified such that they can be used in assays for monitoring hydrolase enzyme activity, and preferably phosphatase activity. Also claimed are modified tyrosine amino acid derivatives of formula (IV), wherein Y is chosen from —POy2? with y equal to 2 or 3 and esters thereof, —SOZ? with z equal to 2 or 3 and esters thereof, a carbohydrate or carbohydrate derivatives; and; wherein X1 and/or X2 is selected from —N3, —NO2, —CI, or —CN, —SCN, a C1 to C8 alkyl, or H, wherein either X1 or X2 is not H.Type: GrantFiled: May 18, 2012Date of Patent: September 20, 2016Assignees: PAMGENE B.V., UNIVERSITEIT UTRECHT HOLDING B.V.Inventors: Robby Ruijtenbeek, Jeroen van Ameijde, Robertus Matthias Joseph Liskamp
-
Patent number: 9128087Abstract: The present invention relates to methods for measuring compound efficacy and potency on nuclear receptor-co-regulator interaction, comprising the steps of (a) co-incubating at least one nuclear receptor and at least one compound under conditions that allow interaction; (b) co-incubating the nuclear receptor-compound mixture of step (a) with an array of co-regulators, under conditions that allow compound modulated receptor-co-regulator interaction; (c) determination of compound-modulated receptor-co-regulator interaction in function B of co-regulator concentration, and (d) determination of compound-modulated receptor-co-regulator interaction in function of compound concentration; wherein steps (c) and (d) are performed in a single assay.Type: GrantFiled: September 10, 2007Date of Patent: September 8, 2015Assignee: PamGene B.V.Inventors: Robby Ruijtenbeek, René Houtman, Marinus Gerardus Johannes Van Beuningen
-
Patent number: 9075061Abstract: The present invention relates to a method for determining the estrogen receptor status of patients suffering from breast cancer. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with breast cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples obtained from patients diagnosed with breast cancer.Type: GrantFiled: April 12, 2010Date of Patent: July 7, 2015Assignee: PamGene B.V.Inventors: Robby Ruijtenbeek, Maria Helena Hilhorst, Arzu Umar, Johannes Albert Foekens, Johannes Wilhelmus Maria Martens
-
Patent number: 8962267Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with non small cell lung cancer to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non small cell lung cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in samples of said patients.Type: GrantFiled: April 12, 2010Date of Patent: February 24, 2015Assignees: Pamgene B.V., Stichting Het Nederlands Kanker InstituutInventors: Richard De Wijn, Robby Ruijtenbeek, Maria Helena Hilhorst, Michael Maria Van Den Heuvel, Houke Marian Klomp
-
Patent number: 8962268Abstract: The present invention relates to a method for determining the survival prognosis of patients suffering from non-small cell lung cancer. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels in response to a kinase inhibitor and profiles in samples obtained from patients diagnosed with non-small cell lung cancer. The present invention also provides methods for predicting the response of a patient diagnosed with non-small cell lung cancer to a medicament.Type: GrantFiled: April 12, 2010Date of Patent: February 24, 2015Assignee: Pamgene B.V.Inventors: Richard De Wijn, Robby Ruijtenbeek, Maria Helena Hilhorst
-
Publication number: 20140342931Abstract: The present invention relates to a method for predicting the response of a patient diagnosed with breast cancer to treatment with an endocrine therapy drug, comprising the steps of: (a) measuring the binding of the estrogen receptor, obtained from a breast cancer tumor from said patient, generating a binding profile, said binding profile comprising the binding of the estrogen receptor from said patient on one or more co-regulator proteins or functional parts thereof in the presence and absence of one or more added phosphatases, (b) measuring the binding of the estrogen receptor, obtained from a breast cancer tumor from said patient, generating a binding profile, said binding profile comprising the binding of the estrogen receptor from said patient on one or more co-regulator proteins or functional parts thereof in the presence and absence of added estradiol, and, (c) predicting from said binding profiles the response of said patient to endocrine drug therapy.Type: ApplicationFiled: September 14, 2012Publication date: November 20, 2014Applicants: PAMGENE B.V., STICHTING HET NEDERLANDS KANKER INSTITUUTInventors: Rene Houtman, Rob Ruijtenbeek, Rob Michalides
-
Publication number: 20140155286Abstract: The present invention relates to a method and tools which allow the kinetic monitoring of hydrolase enzyme activity. The present invention also aims to provide synthetic peptides and peptide residues modified such that they can be used in assays for monitoring hydrolase enzyme activity, and preferably phosphatase activity. Also claimed are modified tyrosine amino acid derivatives of formula (IV), wherein Y is chosen from —POy2? with y equal to 2 or 3 and esters thereof, —SOz? with z equal to 2 or 3 and esters thereof, a carbohydrate or carbohydrate derivatives; and; wherein X1 and/or X2 is selected from —N3, —NO2, —CI, or —CN, —SCN, a C1 to C8 alkyl, or H, wherein either X1 or X2 is not H.Type: ApplicationFiled: May 18, 2012Publication date: June 5, 2014Applicant: PamGene B.V.Inventors: Robby Ruijtenbeek, Jeroen van Ameijde, Robertus Matthias Joseph Liskamp
-
Patent number: 8617836Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with rectal cancer to specific medicaments, radiotherapy and/or chemotherapy. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients.Type: GrantFiled: April 12, 2010Date of Patent: December 31, 2013Assignees: PamGene B.V., Oslo University HospitalInventors: Pieter Jacob Boender, Richard De Wijn, Anne Hansen Ree, Sigurd Folkvord, Kjersti Flatmark, Robby Ruijtenbeek
-
Publication number: 20130217055Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with chronic myelogenous leukaemia (CML) to treatment with a tyrosine kinase inhibitor. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof thereby diagnosing CML patients resistant to treatment with Imatinib.Type: ApplicationFiled: October 17, 2011Publication date: August 22, 2013Applicant: PamGene B.V.Inventors: Pieter Jacob Boender, Adriana Van Den Berg, Robby Ruijtenbeek, Jeroen Johannes Wilhelmus Maria Janssen, Gerrit Johan Ossenkoppele
-
Publication number: 20120046199Abstract: The present invention relates to a method for determining the estrogen receptor status of patients suffering from breast cancer. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with breast cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples obtained from patients diagnosed with breast cancer.Type: ApplicationFiled: April 12, 2010Publication date: February 23, 2012Applicant: PAMGENE B.V.Inventors: Robby Ruijtenbeek, Maria Helena Hilhorst, Arzu Umar, Johannes Albert Foekens, Johannes Wilhelmus Maria Martens
-
Publication number: 20120035076Abstract: The present invention relates to methods and devices for the diagnosis or drug response prediction of neurological disorders by measuring kinase activity and studying the phosphorylation levels and profiles in samples of said patients. Furthermore the present invention relates to methods of identifying drug compounds relevant to neurological disorders by measuring kinase activity and studying phosphorylation levels. Also, the present invention relates to the use of inhibitors of the IRAK protein kinase family or a pharmaceutical composition thereof in the treatment of neurological disorders such as Alzheimer's disease.Type: ApplicationFiled: April 26, 2010Publication date: February 9, 2012Applicants: Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg, Pamgene B.V.Inventors: Maria Helena Hilhorst, Jeroen Joseph Maria Hoozemans, Saskia Maria Van der Vies
-
Patent number: 7504209Abstract: The present invention relates to methods for integrated ribonucleic acid integrity assessment and analysis comprising the steps of: (a) providing a support having immobilized thereon a set of detector probes and a set of at least two control probes, wherein (i) a first of said at least two control probes is complementary to 23S or 28S rRNA or a functionally equivalent RNA, and (ii) a second of said at least two control probes is complementary to 16S or 18S10 rRNA or a functionally equivalent RNA; (b) contacting said support with analyte ribonucleic acids derived from a sample, under conditions allowing hybridisation of complementary analyte ribonucleic acids and immobilized probes to form analyte ribonucleic acid/probe complexes; wherein said hybridisation generates a detectable signal; 15 (c) detecting signals generated by said complexes; (d) determining the ratio of signals generated by the 28S/control probe and 18S rRNA/control probe or 23S rRNA/control probe and 16S rRNA/control probe or functionally equiType: GrantFiled: March 1, 2004Date of Patent: March 17, 2009Assignee: PamGene B.V.Inventors: Colin John Ingham, Richard Michael Anthony
-
Patent number: 7473562Abstract: The present invention relates to methods for monitoring in a high through-put fashion a multitude of molecular reaction processes, using a substrate, said substrate comprising a plurality of micro-channels, wherein each micro-channel has inlet and outlet open ends on opposing sides of said substrate, and wherein said micro-channels comprise at least one first reaction component, comprising the steps of: (a) contacting said micro-channels of said solid substrate with a sample, said contacting being via said inlet open ends, wherein said sample comprises an analyte, under conditions that allow said analyte to be specifically retained within said micro-channels by said first reaction component; (b) optionally removing excess of sample via said outlet open ends; (c) contacting the retained analyte with at least one second reaction component, said second reaction component being different from said first reaction component as defined in step (a), under conditions that allow a molecular reaction to take place, saidType: GrantFiled: June 2, 2003Date of Patent: January 6, 2009Assignee: PamGene B.V.Inventors: Marinus Gerardus Johannus Van Beuningen, Pieter Jacob Boender
-
Patent number: 7364848Abstract: The present invention relates to methods for identifying analyte nucleic acids present in a sample comprising nucleic acid molecules, said method comprising the steps of: (a) providing a porous substrate, said substrate comprising a plurality of micro-channels, wherein said micro-channels have immobilized thereon a target molecule capable of binding to an analyte present in said sample; wherein said channels are further provided with analyte amplification components, a reporter system; and said sample; (b) amplifying analyte nucleic acid molecules present within said sample; and (c) allowing binding to take place between an amplified analyte nucleic acid obtained in step (b), said target molecule immobilized onto the channels of said substrate and said reporter system, wherein said reporter system allows detecting whether binding has occurred between said target molecule and said analyte nucleic acid.Type: GrantFiled: September 1, 2003Date of Patent: April 29, 2008Assignee: PamGene B.V.Inventors: Marinus Gerardus Johannes Van Beuningen, Tim Kievits
-
Patent number: 7105134Abstract: A device for holding a substrate comprises upper and lower plates adapted to receive the substrate sandwiched in the interface between the plates. Each plate has at least one opening with a projecting rim surrounding the opening and directed away from the interface. The openings in the upper and lower plates are preferably at least partially aligned in the sandwiched position of the plates. Each opening in the lower plate can be provided with a shielding member partially shielding the opening of the lower plate.Type: GrantFiled: March 11, 2002Date of Patent: September 12, 2006Assignee: PamGene B.V.Inventors: Hendrik Sibolt van Damme, Wilhelmus Marinus Carpay
-
Patent number: 6849408Abstract: The present invention is directed to methods for analyzing one or more fluid samples for the presence, amount or identity of one or more analytes optionally present in said samples, which uses a device having one or more round wells with a fixed diameter, the wells exposing a substrate of a specific thickness, whereby the substrate has oriented through going channels, in the area of the substrate exposed in the well is provided with at least one binding substance specific for a least one of said analytes. Using the device the sample fluid is forced to pass through the channels in the substrate from the upper side of the substrate to the lower side of the substrate and back at least one time, under conditions that are favorable to a reaction between any analyte present in the sample and the binding substances.Type: GrantFiled: September 24, 2001Date of Patent: February 1, 2005Assignee: PamGene B.V.Inventors: Wilhemus M. Carpay, Roeland F. Papen
-
Patent number: 6635493Abstract: The present invention relates to a device for performing an assay, which device comprises a substrate having oriented through-going channels, said channels opening out on a surface for sample application, the channels in at least one area of the surface for sample application being provided with a first binding substance capable of binding to an analyte. The object of the present invention is to provide a substrate having both a high channel density and a high porosity, allowing high density arrays comprising different first binding substances to be applied to the surface for sample application. More in particular, the object of the present invention is to provide a device comprising a relatively cheap substrate that does not require the use of any typical microfabrication technology and, that offers an improved control over the liquid distribution over the surface of the substrate.Type: GrantFiled: April 30, 2001Date of Patent: October 21, 2003Assignee: PamGene B.V.Inventors: Hendrik Sibolt van Damme, Hermanus Johannes Maria Kreuwel